

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssseptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:54:25 ON 18 JUN 2008

=> file medline, uspatful, dgene, embase, wpids, biosis, scisearch, biotechds, hcaplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 12:55:12 ON 18 JUN 2008

FILE 'USPATFULL' ENTERED AT 12:55:12 ON 18 JUN 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 12:55:12 ON 18 JUN 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 12:55:12 ON 18 JUN 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 12:55:12 ON 18 JUN 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'BIOSIS' ENTERED AT 12:55:12 ON 18 JUN 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 12:55:12 ON 18 JUN 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 12:55:12 ON 18 JUN 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'HCAPLUS' ENTERED AT 12:55:12 ON 18 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s factor VII or Factor VIIa  
L1 78387 FACTOR VII OR FACTOR VIIA

=> s l1 and (mutaion)  
L2 0 L1 AND (MUTAION)

=> s l1 and (muatation)  
L3 0 L1 AND (MUATION)

=> s l1 and (mutation)  
L4 8069 L1 AND (MUTATION)

=> s l4 and (gla domain)

L5 260 L4 AND (GLA DOMAIN)

=> s 15 and (sugar moiety)

L6 28 L5 AND (SUGAR MOIETY)

=> e andersen, a/au

E1 1 ANDERSEN ZORANA J DR/AU  
E2 7 ANDERSEN ZORANA JOVANOVIĆ/AU  
E3 0 --> ANDERSEN, A/AU  
E4 1 ANDERSEN B J/AU  
E5 1 ANDERSEN BAGGE J/AU  
E6 3 ANDERSEN BECKH B/AU  
E7 1 ANDERSEN CU/AU  
E8 1 ANDERSEN F TERREL/AU  
E9 1 ANDERSEN G L H/AU  
E10 1 ANDERSEN GOTT T/AU  
E11 1 ANDERSEN HARILD P/AU  
E12 2 ANDERSEN I DANA C/AU

=> e haaning, j/au

E1 2 HAANING NIELSEN A/AU  
E2 2 HAANING NIELSEN ASBJORN/AU  
E3 0 --> HAANING, J/AU  
E4 1 HAANK D/AU  
E5 2 HAANK DERK/AU  
E6 1 HAANKE/AU  
E7 1 HAANKE M/AU  
E8 1 HAANKE MATHIAS/AU  
E9 1 HAANKETO NIKO/AU  
E10 1 HAANMEULMAN M/AU  
E11 1 HAANNAN MONIQUE/AU  
E12 1 HAANNI W/AU

=> d 16 ti abs ibib tot

L6 ANSWER 1 OF 28 USPATFULL on STN

T1 Factor VII or VIIa - Like Molecules

AB Conjugates of Factor VII (FVII) and Factor

VIIa (FVIIa) are provided, as are methods for preparing them.

Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007:278155 USPATFULL

TITLE: Factor VII or VIIa - Like Molecules

INVENTOR(S): Pedersen, Anders Hjelholt, Lyngby, DENMARK

Andersen, Kim Vilbour, Broenshoej, DENMARK

Bornaes, Claus, Hellerup, DENMARK

PATENT ASSIGNEE(S): Maxygen Holdings, Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070243588	A1	20071018
APPLICATION INFO.:	US 2006-279541	A1	20060412 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-950747, filed on 27 Sep 2004, PENDING Division of Ser. No. US 2001-782587, filed on 12 Feb 2001, GRANTED, Pat. No. US 6806063		

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: DK 2000-218 20000211  
 US 2000-241916P 20001018 (60)  
 US 2000-184036P 20000222 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515  
 GALVESTON DRIVE, REDWOOD CITY, CA, 94063, US

NUMBER OF CLAIMS: 12  
 EXEMPLARY CLAIM: 1-67  
 LINE COUNT: 3388  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 28 USPATFULL on STN  
 TI Factor VII or VIIa-like molecules  
 AB Conjugates of Factor VII (FVII) and Factor  
 VIIa (FVIIa) are provided, as are methods for preparing them.  
 Methods for producing novel polypeptides contributing to the production  
 of such conjugates are provided. Methods of treatment by administering a  
 FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2007:162724 USPATFULL  
 TITLE: Factor VII or VIIa-like molecules  
 INVENTOR(S): Pedersen, Anders Hjelholt, Lyngby, DENMARK  
 Andersen, Kim Vilbour, Copenhagen, DENMARK  
 Bornaes, Claus, Hellerup, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070142280	A1	20070621
APPLICATION INFO.:	US 2006-448143	A1	20060607 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-950747, filed on 27 Sep 2004, PENDING Division of Ser. No. US 2001-782578, filed on 12 Feb 2001, GRANTED, Pat. No. US 6662275		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-218	20000211
	US 2000-241916P	20001018 (60)
	US 2000-184036P	20000222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, REDWOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1-67	
LINE COUNT:	3469	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 3 OF 28 USPATFULL on STN  
 TI FVII or FVIIa Gla domain variants  
 AB Gla domain variants of human Factor  
 VII or human Factor VIIa, comprising 1-15  
 amino acid modifications relative to human Factor VII  
 or human Factor VIIa, wherein a hydrophobic amino  
 acid residue has been introduced by substitution in position 34; or  
 having an amino acid substitution in position 36; and use of the  
 variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2007:135074 USPATFULL

TITLE: FVII or FVIIa Gla domain variants  
 INVENTOR(S): Haaning, Jesper Mortensen, Birkerød, DENMARK  
 Andersen, Kim Vilbour, Broenshoej, DENMARK  
 Bornaes, Claus, Hellerup, DENMARK  
 PATENT ASSIGNEE(S): Maxygen Holdings, Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070117756	A1	20070524
APPLICATION INFO.:	US 2006-643535	A1	20061221 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-21239, filed on 22 Dec 2004, PENDING Continuation-in-part of Ser. No. WO 2004-DK428, filed on 18 Jun 2004, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2004-930	20040615
	US 2003-479780P	20030619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, REDWOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1-20	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2307	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 4 OF 28 USPATFULL on SIN  
 TI Fvii or fviiia variants  
 AB Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237 or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2007:62231 USPATFULL  
 TITLE: Fvii or fviiia variants  
 INVENTOR(S): Andersen, Kim Vilbour, Broenshoej, DENMARK  
 Ropke, Mads, Frederiksberg, DENMARK  
 Haaning, Jesper Mortensen, Birkerød, DENMARK  
 Glazer, Steven, Copenhagen K, DENMARK  
 PATENT ASSIGNEE(S): MAXYGEN HOLDINGS LTD., Grand Cayman, CAYMAN ISLANDS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070054366	A1	20070308
APPLICATION INFO.:	US 2004-549506	A1	20040322 (10)
	WO 2004-DK193		20040322
			20060707 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-456547P	20030320 (60)
	US 2003-479708P	20030619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, REDWOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	29	

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Page(s)  
LINE COUNT: 2124  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 28 USPATFULL on STN  
TI Factor VII or VIIa Polypeptide Variants  
AB The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:322332 USPATFULL  
TITLE: Factor VII or VIIa Polypeptide Variants  
INVENTOR(S): Haaning, Jesper Mortensen, Biskop Svanesvej 2E, Birkerød, DENMARK DK-3460  
Andersen, Kim Vilbourn, Karlstad AllA.COPYRG.T. 7, Broenshoej, DENMARK DK-2700  
PATENT ASSIGNEE(S): Maxygen Holdings, Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060276377	A1	20061207
APPLICATION INFO.:	US 2006-381718	A1	20060504 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2005-512754, filed on 11 Jul 2005, PENDING A 371 of International Ser. No. WO 2003-DK267, filed on 29 Apr 2003		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-376679P	20020430 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	

NUMBER OF CLAIMS: 31  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2955  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 28 USPATFULL on STN  
TI Factor VII or VIIa Polypeptide Variants  
AB The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:315219 USPATFULL

TITLE: Factor VII or VIIa Polypeptide Variants  
 INVENTOR(S): Haaning, Jesper Mortensen, Biskop Svanesvej 2E, Birkerød, DENMARK DK-3460  
 Andersen, Kim Vilbourn, Karlstad AllA.COPYRGT. 7, Broenshoej, DENMARK DK-2700  
 PATENT ASSIGNEE(S): Maxygen Holdings, Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060270002	A1	20061130
APPLICATION INFO.:	US 2006-381717	A1	20060504 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2005-512754, filed on 11 Jul 2005, PENDING A 371 of International Ser. No. WO 2003-DK267, filed on 29 Apr 2003		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-376679P	20020430 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2953	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 7 OF 28 USPATFULL on SIN  
 TI Factor VII or VIIa Polypeptide Variants  
 AB The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2006:315218 USPATFULL  
 TITLE: Factor VII or VIIa Polypeptide Variants  
 INVENTOR(S): Haaning, Jesper Mortensen, Biskop Svanesvej 2E, Birkerød, DENMARK DK-3460  
 Andersen, Kim Vilbourn, Karlstad AllA.COPYRGT. 7, Broenshoej, DENMARK DK-2700  
 PATENT ASSIGNEE(S): Maxygen Holdings, Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060270001	A1	20061130
APPLICATION INFO.:	US 2006-381713	A1	20060504 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2005-512754, filed on 11 Jul 2005, PENDING A 371 of International Ser. No. WO 2003-DK267, filed on 29 Apr 2003		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-376679P	20020430 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515  
GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US  
NUMBER OF CLAIMS: 31  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2962  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 28 USPATFULL on SIN  
TI Factor VII or VIIa Polypeptide Variants  
AB The present invention relates to novel polypeptide variants of  
factor VII (FVII) or factor VIIa  
(FVIIa) polypeptides, where said variants comprise an amino acid  
substitution in position 10 and 32 and where said variants further  
comprise a sugar moiety covalently attached to an  
introduced in vivo N-glycosylation site located outside of the  
Gla domain. Such polypeptide variants are useful in  
therapy, in particular for the treatment of a variety of  
coagulation-related disorders, such as trauma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:315217 USPATFULL  
TITLE: Factor VII or VIIa Polypeptide  
Variants  
INVENTOR(S): Haaning, Jesper Mortensen, Biskop Svanesvej 2E,  
Birkeroed, DENMARK DK-3460  
Andersen, Kim Vilbour, Karlstad Alla.COPYRG. 7,  
Broenshoej, DENMARK DK-2700  
PATENT ASSIGNEE(S): Maxygen Holdings, Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060270000	A1	20061130
APPLICATION INFO.:	US 2006-381705	A1	20060504 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2005-512754, filed on 11 Jul 2005, PENDING A 371 of International Ser. No. WO 2003-DK267, filed on 29 Apr 2003		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-376679P	20020430 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2954	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 28 USPATFULL on SIN  
TI Factor VII or VIIa-like molecules  
AB Conjugates of Factor VII (FVII) and Factor  
VIIa (FVIIa) are provided, as are methods for preparing them.  
Methods for producing novel polypeptides contributing to the production  
of such conjugates are provided. Methods of treatment by administering a  
FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:302225 USPATFULL



TITLE: Factor VII or VIIa-like molecules  
 INVENTOR(S): Pedersen, Anders Hjelholt, Lyngby, DENMARK  
 Andersen, Kim Vilbour, Broenshoej, DENMARK  
 Bornaes, Claus, Hellerup, DENMARK  
 PATENT ASSIGNEE(S): Maxygen Holdings, Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060258585	A1	20061116
APPLICATION INFO.:	US 2006-396314	A1	20060330 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-950747, filed on 27 Sep 2004, PENDING Division of Ser. No. US 2001-782587, filed on 12 Feb 2001, GRANTED, Pat. No. US 6806063		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-218	20000211
	US 2000-241916P	20001018 (60)
	US 2000-184036P	20000222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1-67	
LINE COUNT:	3370	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 10 OF 28 USPATFULL on STN  
 TI Factor VII or VIIa - Like Molecules  
 AB Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2006:295520 USPATFULL  
 TITLE: Factor VII or VIIa - Like Molecules  
 INVENTOR(S): Pedersen, Anders Hjelholt, 58 Nybrovaenget, Lyngby, DENMARK DK-2800  
 Andersen, Kim Vilbour, Karlstad Alla.COPYRGT. 7, Broenshoej, DENMARK DK-2700  
 Bornaes, Claus, 6 Hoejgaards Alla.COPYRGT., Hellerup, DENMARK DK-2900  
 PATENT ASSIGNEE(S): MAXYGEN HOLDINGS, LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060252690	A1	20061109
APPLICATION INFO.:	US 2006-426401	A1	20060626 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-950747, filed on 27 Sep 2004, PENDING Division of Ser. No. US 2001-782587, filed on 12 Feb 2001, GRANTED, Pat. No. US 6806063		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-218	20000211
	US 2000-184036P	20000222 (60)
	US 2000-241916P	20001018 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515  
GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US  
NUMBER OF CLAIMS: 3  
EXEMPLARY CLAIM: 1-56  
LINE COUNT: 3338  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 28 USPATFULL on STN  
TI Factor VII or VIIa - Like Molecules  
AB Conjugates of Factor VII (FVII) and Factor  
VIIa (FVIIa) are provided, as are methods for preparing them.  
Methods for producing novel polypeptides contributing to the production  
of such conjugates are provided. Methods of treatment by administering a  
FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:295519 USPATFULL  
TITLE: Factor VII or VIIa - Like Molecules  
INVENTOR(S): Pedersen, Anders Hjelholt, 58 Nybrovaenget, Lyngby,  
DENMARK DK-2800  
Andersen, Kim Vilbourn, Karlstad Alla.COPYRG. 7,  
Broenshoej, DENMARK DK-2700  
Bornaes, Claus, 6 Hoejgaards Alla.COPYRG., Hellerup,  
DENMARK DK-2900  
PATENT ASSIGNEE(S): MAXYGEN HOLDINGS, LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060252689	A1	20061109
APPLICATION INFO.:	US 2006-426394	A1	20060626 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-950747, filed on 27 Sep 2004, PENDING Division of Ser. No. US 2001-782587, filed on 12 Feb 2001, GRANTED, Pat. No. US 6806063		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-218	20000211
	US 2000-184036P	20000222 (60)
	US 2000-241916P	20001018 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515  
GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US  
NUMBER OF CLAIMS: 59  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3550  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 28 USPATFULL on STN  
TI FVII OR FVIIa GLA DOMAIN VARIANTS  
AB GLA domain variants of human Factor  
VII or human Factor VIIa, comprising 1-15  
amino acid modifications relative to human Factor VII  
or human Factor VIIa, wherein a hydrophobic amino  
acid residue has been introduced by substitution in position 34; or  
having an amino acid substitution in position 36; and use of the  
variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:294962 USPATFULL

TITLE: FVII OR FVIIa GLA DOMAIN VARIANTS  
 INVENTOR(S): Haaning, Jesper Mortensen, Biskop Svanesvej 2E,  
 Birkerød, DENMARK DK-3460  
 Andersen, Kim Vilbourn, Karlstad AllA.COPYRGT. 7,  
 Broenshoej, DENMARK DK-2700  
 Bornaes, Claus, 6 Hoejgaards AllA.COPYRGT., Hellerup,  
 DENMARK DK-2900  
 PATENT ASSIGNEE(S): Maxygen Holdings Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060252128	A1	20061109
APPLICATION INFO.:	US 2006-379664	A1	20060421 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-21239, filed on 22 Dec 2004, PENDING Continuation-in-part of Ser. No. WO 2004-DK428, filed on 18 Jun 2004, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2004-930	20040615
	US 2003-479780P	20030619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2382	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 13 OF 28 USPATFULL on STN  
 TI Factor VII or VIIa - Like Molecules  
 AB Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2006:294961 USPATFULL  
 TITLE: Factor VII or VIIa - Like Molecules  
 INVENTOR(S): Pedersen, Anders Hjelholt, 58 Nybrovaenget, Lyngby, DENMARK DK-2800  
 Andersen, Kim Vilbourn, Karlstad AllA.COPYRGT. 7,  
 Broenshoej, DENMARK DK-2700  
 Bornaes, Claus, 6 Hoejgaards AllA.COPYRGT., Hellerup, DENMARK DK-2900  
 PATENT ASSIGNEE(S): Maxygen Holdings, Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060252127	A1	20061109
APPLICATION INFO.:	US 2006-379189	A1	20060418 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-950747, filed on 27 Sep 2004, PENDING Division of Ser. No. US 2001-782587, filed on 12 Feb 2001, GRANTED, Pat. No. US 6806063		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-218	20000211

US 2000-241916P 20001018 (60)  
 US 2000-184036P 20000222 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515  
 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US  
 NUMBER OF CLAIMS: 15  
 EXEMPLARY CLAIM: 1-67  
 LINE COUNT: 3382  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 28 USPATFULL on STN  
 TI FVII OR FVIIA GLA DOMAIN VARIANTS  
 AB Gla domain variants of human Factor  
 VII or human Factor VIIa, comprising 1-15  
 amino acid modifications relative to human Factor VII  
 or human Factor VIIa, wherein a hydrophobic amino  
 acid residue has been introduced by substitution in position 34; or  
 having an amino acid substitution in position 36; and use of the  
 variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:282098 USPATFULL  
 TITLE: FVII OR FVIIA GLA DOMAIN VARIANTS  
 INVENTOR(S): Haaning, Jesper Mortensen, Biskop Svanesvej 2E,  
 Birkerød, DENMARK DK-3460  
 Andersen, Kim Vilbourn, Karlstad Alla.COPYRGT. 7,  
 Broenshoej, DENMARK DK-2700  
 Bornaes, Claus, 6 Hoejgaards Alla.COPYRGT., Hellerup,  
 DENMARK DK-2900  
 PATENT ASSIGNEE(S): MAXYGEN HOLDINGS LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060241041	A1	20061026
APPLICATION INFO.:	US 2006-424035	A1	20060614 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-21239, filed on 22 Dec 2004, PENDING Continuation-in-part of Ser. No. WO 2004-DK428, filed on 18 Jun 2004, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2004-930	20040615
	US 2003-479780P	20030619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1-25	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2321	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 15 OF 28 USPATFULL on STN  
 TI FVII OR FVIIA GLA DOMAIN VARIANTS  
 AB Gla domain variants of human Factor  
 VII or human Factor VIIa, comprising 1-15  
 amino acid modifications relative to human Factor VII  
 or human Factor VIIa, wherein a hydrophobic amino  
 acid residue has been introduced by substitution in position 34; or

having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:281586 USPATFULL  
TITLE: FVII OR FVIIA GLA DOMAIN VARIANTS  
INVENTOR(S): Haaning, Jesper Mortensen, Biskop Svanesvej 2E,  
Birkeroed, DENMARK DK-3460  
Andersen, Kim Vilbour, Karlstad Alla.COPYRGT. 7,  
Broenshoej, DENMARK DK-2700  
Bornaes, Claus, 6 Hoejgaards Alla.COPYRGT., Hellerup,  
DENMARK DK-2900  
PATENT ASSIGNEE(S): MAXYGEN HOLDINGS LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060240526	A1	20061026
APPLICATION INFO.:	US 2006-424030	A1	20060614 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-21239, filed on 22 Dec 2004, PENDING Continuation-in-part of Ser. No. WO 2004-DK428, filed on 18 Jun 2004, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2004-930	20040615
	US 2003-479780P	20030619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1-20	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2323	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 28 USPATFULL on STN  
TI Factor VII or VIIa - Like Molecules  
AB Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them.  
Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:281585 USPATFULL  
TITLE: Factor VII or VIIa - Like Molecules  
INVENTOR(S): Pedersen, Anders Hjelholt, 58 Nybrovaenget, Lyngby,  
DENMARK DK-2800  
Andersen, Kim Vilbour, Karlstad Alla.COPYRGT. 7,  
Broenshoej, DENMARK DK-2700  
Bornaes, Claus, 6 Hoejgaards Alla.COPYRGT., Hellerup,  
DENMARK DK-2900  
PATENT ASSIGNEE(S): MAXYGEN HOLDINGS, LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060240525	A1	20061026
APPLICATION INFO.:	US 2006-423665	A1	20060612 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-950747, filed on 27 Sep 2004, PENDING Division of Ser. No. US 2001-782587,		

filed on 12 Feb 2001, GRANTED, Pat. No. US 6806063

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-218	20000211
	US 2000-241916P	20001018 (60)
	US 2000-184036P	20000222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1-63	
LINE COUNT:	3351	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 17 OF 28 USPATFULL on STN  
TI Factor VII or VIIa - Like Molecules  
AB Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them.  
Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2006:281584 USPATFULL  
TITLE: Factor VII or VIIa - Like Molecules  
INVENTOR(S): Pedersen, Anders Hjelholt, 58 Nybrovaenget, Lyngby, DENMARK DK-2800  
Andersen, Kim Vilbour, Karlstad Alla.COPYRGT. 7, Broenshoej, DENMARK DK-2700  
Bornaes, Claus, 6 Hoejgaards Alla.COPYRGT., Hellerup, DENMARK DK-2900  
PATENT ASSIGNEE(S): MAXYGEN HOLDINGS, LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060240524	A1	20061026
APPLICATION INFO.:	US 2006-423662	A1	20060612 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-950747, filed on 27 Sep 2004, PENDING Division of Ser. No. US 2001-782587, filed on 12 Feb 2001, GRANTED, Pat. No. US 6806063		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-218	20000211
	US 2000-241916P	20001018 (60)
	US 2000-184036P	20000222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1-61	
LINE COUNT:	3344	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 18 OF 28 USPATFULL on STN  
TI Factor VII or VIIa - Like Molecules  
AB Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them.

Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:268098 USPATFULL  
TITLE: Factor VII or VIIa - Like Molecules  
INVENTOR(S): Pedersen, Anders Hjelholt, 58 Nybrovaenget, Lyngby, DENMARK DK-2800  
Andersen, Kim Vilbour, Karlstad Alla.COPYRG. 7, Broenshoej, DENMARK DK-2700  
Bornaes, Claus, 6 Hoejgaards Alla.COPYRG., Hellerup, DENMARK DK-2900  
PATENT ASSIGNEE(S): MAXYGEN HOLDINGS, LTD. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060228782	A1	20061012
APPLICATION INFO.:	US 2006-423622	A1	20060612 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-950747, filed on 27 Sep 2004, PENDING Division of Ser. No. US 2001-782587, filed on 12 Feb 2001, GRANTED, Pat. No. US 6806063		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-218	20000211
	US 2000-241916P	20001018 (60)
	US 2000-184036P	20000222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1-57	
LINE COUNT:	3328	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 28 USPATFULL on STN

TI Fvii or fviiia variants having increased clotting activity

AB The present invention relates to novel Factor VII or VIIa variants comprising a substitution in at least one position selected from the group consisting of L39, I42, S43, K62, L65, F71, E82 and F275. Such variants exhibit increased clotting activity as compared to human wild-type Factor VIIa. The present invention also relates to use of such Factor VII or VIIa variants in therapy, in particular for the treatment of a variety of coagulation-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:196118 USPATFULL  
TITLE: Fvii or fviiia variants having increased clotting activity  
INVENTOR(S): Haaning, Jesper Mortensen, Birkerød, DENMARK  
Andersen, Kim Vilbour, Broenshoej, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060166874	A1	20060727
APPLICATION INFO.:	US 2003-529624	A1	20030926 (10)
	WO 2003-DK632		20030926
			20051013 PCT 371 date

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2002-60414836	20020930
	US 2003-60479642	20030619
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	3359	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 20 OF 28 USPATFULL on STN

TI Factor vii or viia polypeptide variants

AB The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2006:131640	USPATFULL
TITLE:	Factor vii or viia polypeptide variants	
INVENTOR(S):	Haaning, Jesper Mortensen, Birkerød, DENMARK	
	Andersen, Kim Vilbourn, Broenshoej, DENMARK	
PATENT ASSIGNEE(S):	Maxygen Holdings Ltd. (non-U.S. corporation)	

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 20060111282	A1	20060525
APPLICATION INFO.:	US 2003-512754	A1	20030429 (10)
	WO 2003-DK276		20030429
			20050711 PCT 371 date

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2002-60376679	20020430
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3037	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 21 OF 28 USPATFULL on STN

TI Novel proteins and nucleic acids encoding same

AB The present invention provides novel isolated polynucleotides and small molecule target polypeptides encoded by the polynucleotides. Antibodies that immunospecifically bind to a novel small molecule target polypeptide or any derivative, variant, mutant or fragment of that polypeptide, polynucleotide or antibody are disclosed, as are methods in



which the small molecule target polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states. More specifically, the present invention discloses methods of using recombinantly expressed and/or endogenously expressed proteins in various screening procedures for the purpose of identifying therapeutic antibodies and therapeutic small molecules associated with diseases. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:98887 USPATFULL  
TITLE: Novel proteins and nucleic acids encoding same  
INVENTOR(S): Alsobrook, John, Madison, CT, UNITED STATES  
Anderson, David, Plantsville, CT, UNITED STATES  
Baumgartner, Jason, New Haven, CT, UNITED STATES  
Berghs, Constance, New Haven, CT, UNITED STATES  
Boldog, Ferenc, North Haven, CT, UNITED STATES  
Burgess, Catherine, Wethersfield, CT, UNITED STATES  
Casman, Stacie, North Haven, CT, UNITED STATES  
Catterton, Elina, Milford, CT, UNITED STATES  
Dhanabal, Mohanraj, Branford, CT, UNITED STATES  
Edinger, Shlomit, New Haven, CT, UNITED STATES  
Ellerman, Karen, Branford, CT, UNITED STATES  
Ettenberg, Seth, New Haven, CT, UNITED STATES  
Gangolli, Esha, Acton, MA, UNITED STATES  
Gerlach, Valerie, Branford, CT, UNITED STATES  
Gorman, Linda, Branford, CT, UNITED STATES  
Grosse, William, Branford, CT, UNITED STATES  
Gunther, Erik, Branford, CT, UNITED STATES  
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES  
Gusev, Vladimir, Madison, CT, UNITED STATES  
Herrmann, John, Guilford, CT, UNITED STATES  
Ji, Weizhen, Branford, CT, UNITED STATES  
Kekuda, Ramesh, Stamford, CT, UNITED STATES  
Khramtsov, Nikolai, Branford, CT, UNITED STATES  
LaRochelle, William, Madison, CT, UNITED STATES  
Li, Li, Branford, CT, UNITED STATES  
Liang, Hongping, Hamden, CT, UNITED STATES  
Low, Kenneth, New Haven, CT, UNITED STATES  
MacDougall, John, Hamden, CT, UNITED STATES  
MacLachlan, Timothy, Unionville, CT, UNITED STATES  
Malyankar, Uriel, North Branford, CT, UNITED STATES  
McQueeney, Kelly, Ansonia, CT, UNITED STATES  
Mezick, Amanda, Hamden, CT, UNITED STATES  
Miller, Charles, Guilford, CT, UNITED STATES  
Millet, Isabelle, Milford, CT, UNITED STATES  
Padigaru, Muralidhara, Branford, CT, UNITED STATES  
Patturajan, Meera, Branford, CT, UNITED STATES  
Peyman, John, New Haven, CT, UNITED STATES  
Qian, Xiaozhong, Branford, CT, UNITED STATES  
Rastelli, Luca, Guilford, CT, UNITED STATES  
Rieger, Daniel, Branford, CT, UNITED STATES  
Rothenberg, Mark, Clinton, CT, UNITED STATES  
Shenoy, Suresh, Branford, CT, UNITED STATES  
Shimkets, Richard, Guilford, CT, UNITED STATES  
Smithson, Glenna, Guilford, CT, UNITED STATES  
Spytek, Kimberly, Ellington, CT, UNITED STATES  
Stone, David, Guilford, CT, UNITED STATES  
Sukumaran, Sujatha, Branford, CT, UNITED STATES  
Szekeres, Edward S. JR., Walling Ford, CT, UNITED STATES

STATES  
 Vernet, Corine, Chernex, SWITZERLAND  
 Voss, Edward, Wallingford, CT, UNITED STATES  
 Wolenc, Adam R., New Haven, CT, UNITED STATES  
 Zhong, Mei, Branford, CT, UNITED STATES  
 Zhong, Haihong, Guilford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060084054	A1	20060420
APPLICATION INFO.:	US 2003-455772	A1	20030604 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-669360, filed on 26 Sep 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-385615P	20020604 (60)
	US 2002-402268P	20020809 (60)
	US 2002-387606P	20020611 (60)
	US 2002-386357P	20020606 (60)
	US 2002-385755P	20020604 (60)
	US 2002-386355P	20020606 (60)
	US 2002-385490P	20020604 (60)
	US 2002-420718P	20021023 (60)
	US 2002-386447P	20020606 (60)
	US 2002-386465P	20020606 (60)
	US 2002-420627P	20021023 (60)
	US 2002-386459P	20020606 (60)
	US 2002-410505P	20020913 (60)
	US 2002-420852P	20021024 (60)
	US 2002-386796P	20020607 (60)
	US 2002-387078P	20020607 (60)
	US 2002-387083P	20020607 (60)
	US 2002-387081P	20020607 (60)
	US 2002-386041P	20020605 (60)
	US 2002-386701P	20020607 (60)
	US 2002-387610P	20020611 (60)
	US 2002-387540P	20020610 (60)
	US 2002-387429P	20020610 (60)
	US 2002-410085P	20020912 (60)
	US 2002-389120P	20020614 (60)
	US 2002-386931P	20020607 (60)
	US 2002-387866P	20020610 (60)
	US 2002-387859P	20020611 (60)
	US 2002-387659P	20020611 (60)
	US 2002-387934P	20020612 (60)
	US 2002-387696P	20020611 (60)
	US 2002-390006P	20020619 (60)
	US 2002-389604P	20020618 (60)
	US 2002-387668P	20020611 (60)
	US 2002-386864P	20020606 (60)
	US 2002-401628P	20020806 (60)
	US 2002-406182P	20020826 (60)
	US 2002-412955P	20020923 (60)
	US 2002-415195P	20020930 (60)
	US 2002-422750P	20021031 (60)
	US 2002-390144P	20020619 (60)
	US 2002-388022P	20020612 (60)
	US 2002-402822P	20020812 (60)
	US 2002-388096P	20020612 (60)
	US 2002-389123P	20020613 (60)

US 2002-390209P 20020619 (60)  
 US 2002-388479P 20020612 (60)  
 US 2002-403458P 20020813 (60)  
 US 2002-389884P 20020618 (60)  
 US 2002-389146P 20020614 (60)  
 US 2002-387960P 20020612 (60)  
 US 2002-388432P 20020612 (60)  
 US 2002-403617P 20020815 (60)  
 US 2002-423095P 20021101 (60)  
 US 2002-423748P 20021105 (60)  
 US 2002-391726P 20020625 (60)  
 US 2002-403732P 20020815 (60)  
 US 2002-389742P 20020617 (60)  
 US 1999-156217P 19990927 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Jenell Lawson, Intellectual Property, CURAGEN CORPORATION, 555 Long Wharf Drive, New Haven, CT, 06551, US

NUMBER OF CLAIMS: 45  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 5 Drawing Page(s)  
 LINE COUNT: 68810  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 28 USPATFULL ON STN  
 T1 Factor VII or VIIa - like molecules  
 AB Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2006:21503 USPATFULL  
 TITLE: Factor VII or VIIa - like molecules  
 INVENTOR(S): Pedersen, Anders Hjelholt, Lyngby, DENMARK  
 Andersen, Kim Vilbourn, Broenshoej, DENMARK  
 Bornaes, Claus, Hellerup, DENMARK  
 PATENT ASSIGNEE(S): Maxygen ApS (non-U.S. corporation)  
 Maxygen Holdings, Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060019336	A1	20060126
	US 7371543	B2	20080513
APPLICATION INFO.:	US 2004-950747	A1	20040927 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-782587, filed on 12 Feb 2001, GRANTED, Pat. No. US 6806063		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-218	20000211
	US 2000-241916P	20001018 (60)
	US 2000-184036P	20000222 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US  
 NUMBER OF CLAIMS: 25  
 EXEMPLARY CLAIM: 1-67

LINE COUNT: 3405  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 28 USPATFULL on STN  
TI FVII or FVIIa Gla domain variants  
AB Gla domain variants of human Factor  
VII or human Factor VIIa, comprising 1-15  
amino acid modifications relative to human Factor VII  
or human Factor VIIa, wherein a hydrophobic amino  
acid residue has been introduced by substitution in position 34; or  
having an amino acid substitution in position 36; and use of the  
variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:190016 USPATFULL  
TITLE: FVII or FVIIa Gla domain variants  
INVENTOR(S): Haaning, Jesper Mortensen, Birkerød, DENMARK  
Andersen, Kim Vilbourn, Broenshoej, DENMARK  
Bornaes, Claus, Hellerup, DENMARK  
PATENT ASSIGNEE(S): Maxygen Holdings, Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050164932	A1	20050728
APPLICATION INFO:	US 2004-21239	A1	20041222 (11)
RELATED APPLN. INFO:	Continuation-in-part of Ser. No. WO 2004-DK428, filed on 18 Jun 2004, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2004-930	20040615
	US 2003-479780P	20030619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2381	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 28 USPATFULL on STN  
TI Protein C or activated protein C-like molecules  
AB The present invention relates to novel conjugates between polypeptide  
variants of protein C and a non-polypeptide moiety, such as PEG or sugar  
moieties. In particular, the present invention provides novel protein C  
conjugates having an increased resistance to inactivation by e.g. human  
plasma and  $\alpha$ .sub.1-antitrypsin. Consequently, such conjugates have  
an increased in vivo half-life. Preferred examples include protein C  
conjugates, wherein at least one additional in vivo N-glycosylation site  
has been introduced. The conjugates of the invention are useful for  
treating a variety of diseases, including septic shock.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:111589 USPATFULL  
TITLE: Protein C or activated protein C-like molecules  
INVENTOR(S): Andersen, Kim Vilbourn, Broenshoej, DENMARK  
Pedersen, Anders Hjelholt, Lyngby, DENMARK  
Freskgaard, Per Ola, Vellinge, SWEDEN  
PATENT ASSIGNEE(S): Maxygen ApS (non-U.S. corporation)

Maxygen Holdings Ltd. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050095668	A1	20050505
	US 7226999	B2	20070605
APPLICATION INFO.:	US 2004-4111	A1	20041203 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-997623, filed on 29 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-978917, filed on 17 Oct 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-970	20010621
	DK 2000-1560	20001018
	US 2001-300154P	20010621 (60)
	US 2000-242268P	20001018 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	3474	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L6 ANSWER 25 OF 28 USPATFULL on STN

TI Novel nucleic acids and polypeptides

AB The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:58174 USPATFULL

TITLE: Novel nucleic acids and polypeptides

INVENTOR(S): Tang, Y. Tom, San Jose, CA, UNITED STATES  
Liu, Chenghua, San Jose, CA, UNITED STATES  
Asundi, Vinod, Foster City, CA, UNITED STATES  
Wehrman, Tom, Stanford, CA, UNITED STATES  
Ren, Feiyan, Cupertino, CA, UNITED STATES  
Zhou, Ping, Cupertino, CA, UNITED STATES  
Zhao, Qing A., San Jose, CA, UNITED STATES  
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES  
Zhang, Jie, Campbell, CA, UNITED STATES  
Xue, Aidong, Sunnyvale, CA, UNITED STATES  
Wang, Jian-Rui, Cupertino, CA, UNITED STATES  
Wang, Dunrui, Poway, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040044181	A1	20040304
APPLICATION INFO.:	US 2003-363616	A1	20030715 (10)
	WO 2001-US27093		20010831
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NUVELO, 675 ALMANOR AVE., SUNNYVALE, CA, 94085		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
LINE COUNT:	17667		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L6 ANSWER 26 OF 28 USPATFULL on STN  
 TI Factor VII or VIIa-like molecules  
 AB Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:140497 USPATFULL  
 TITLE: Factor VII or VIIa-like molecules  
 INVENTOR(S): Pedersen, Anders Hjelholt, Lyngby, DENMARK  
 Andersen, Kim Vilbourn, Copenhagen, DENMARK  
 Bornaes, Claus, Hellerup, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030096338	A1	20030522
	US 6806063	B2	20041019
APPLICATION INFO.:	US 2001-782587	A1	20010212 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-218	20000211
	US 2000-184036P	20000222 (60)
	US 2000-241916P	20001018 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063	
NUMBER OF CLAIMS:	67	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3559	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 28 USPATFULL on STN  
 TI Protein C or activated protein C-like molecules  
 AB The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and  $\alpha$ .sub.1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:37654 USPATFULL  
 TITLE: Protein C or activated protein C-like molecules  
 INVENTOR(S): Andersen, Kim Vilbourn, Broenshoej, DENMARK  
 Pedersen, Anders Hjelholt, Lyngby, DENMARK  
 Freskgaard, Per Ola, Vellinge, SWEDEN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030027299	A1	20030206
APPLICATION INFO.:	US 2001-978917	A1	20011017 (9)

NUMBER	DATE
-----	-----

PRIORITY INFORMATION: DK 2000-1560 20001018  
 DK 2001-970 20010621  
 US 2000-242268P 20001018 (60)  
 US 2001-300154P 20010621 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: MAXYGEN, INC., 515 GALVESTON DRIVE, RED WOOD CITY, CA,  
 94063  
 NUMBER OF CLAIMS: 52  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 4 Drawing Page(s)  
 LINE COUNT: 3394  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 28 USPATFULL ON STN  
 TI Protein C or activated protein C-like molecules  
 AB The present invention relates to novel conjugates between polypeptide variants of protein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and  $\alpha$ .sub.1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 ACCESSION NUMBER: 2003:24331 USPATFULL  
 TITLE: Protein C or activated protein C-like molecules  
 INVENTOR(S): Andersen, Kim Vilbour, Broenshoej, DENMARK  
 Pedersen, Anders Hjelholt, Lyngby, DENMARK  
 Freskgaard, Per Ola, Vellinge, SWEDEN  
 PATENT ASSIGNEE(S): Maxygen ApS, Hoersholm, DENMARK (3)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030018175	A1	20030123
	US 6933367	B2	20050823
APPLICATION INFO.:	US 2001-997623	A1	20011129 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-978917, filed on 17 Oct 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-1560	20001018
	DK 2000-200100970	20000621
	US 2001-300154P	20010621 (60)
	US 2000-242268P	20001018 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAXYGEN, INC., 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	3670	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		